IMIM - Institut Hospital del Mar d'Investigacions Mèdiques IMIM - Institut Hospital del Mar d'Investigacions Mèdiques


  • 13/05/2019 - Events

    A conference to promote women's research in computational biology

    BSC, UPC and IMIM organize the first Advances in Computational Biology conference will bring together researchers working on systems biology, omics technologies, artificial intelligence and high-performance computing (HPC) with applications to biology from both the public and the private sectors. The conference will be held November 28-29 in La Pedrera (Barcelona). Maria Jose Rementeria, Social Link Analytics group leader at the Barcelona Supercomputing Center (BSC) and one of the organizers, states: "One of the main purposes of the conference is to visualize and promote the research done by women scientists and for this reason all presenters will be women, although the conference is open to everyone. We want to create a space to foster collaborations between scientists, providing a unique opportunity to share ideas and build research networks".

    Més informació "A conference to promote women's research in computational biology"

  • Events

    Immunotherapy for treating the most aggressive breast cancer

    Immunotherapy, the use of the patient's own immune system to attack tumour cells is the method chosen by the Hospital del Mar and its research centre, the Hospital del Mar Medical Research Institute (IMIM) in their search for new breast cancer treatments. They are looking in particular at triple negative breast cancer, one of the most aggressive types, which, in addition, affects younger patients and is the breast tumour with the fewest therapeutic targets for oncologists. This commitment has received a strong boost thanks to the grant the Cancer Research Institute (CRI) has just awarded the project "LCOR orchestrates the differential IFN-a response and immunological properties of triple-negative breast cancer cells", led by Dr. Toni Celià-Terrassa, a researcher in the Molecular Therapy of Cancer group, directed by Dr. Joan Albanell, head of medical oncology at Hospital del Mar and director of the IMIM's Cancer Research programme.

    Més informació "Immunotherapy for treating the most aggressive breast cancer"

  • 04/05/2017 - Events

    Mutation discovered that, linked with drug, predisposes osteoporosis patients to femur fracture

    Researchers at the Hospital del Mar Medical Research Institute (IMIM) and the University of Barcelona have uncovered a mutation that makes bone vulnerable to bisphosphonates, drugs used to combat osteoporosis. Instead of strengthening bone and preventing fractures, these medicines induce a critical problem that makes the femur more prone to breaks. This discovery, enormously significant clinically, was published today in the New England Journal of Medicine, the most important biomedical journal in terms of potential impact. Osteoporosis causes fractures that affect up to 40% of people over the age of 50. Bisphosphonates are efficient and cheap, making them the first line of treatment for this condition. Nevertheless, they have been associated with atypical fracturing of the femur. "Despite the rarity of this complication and the fact that many more fractures are prevented than induced, fear of this complication has led to the prescription of these drugs being criticised, especially for long-term treatment", explains study leader Dr. Adolf Díez, emeritus head of internal medicine at Hospital del Mar and a researcher in the musculoskeletal research group at the IMIM. 

    Més informació "Mutation discovered that, linked with drug, predisposes osteoporosis patients to femur fracture"

  • 26/05/2016 - Events

    Biomarker discovered that measures the risk of cancer in non-smokers

    Researchers from the Hospital del Mar Medical Research Institute (IMIM) have, for the first time, demonstrated that measurements of a tobacco-specific nitrosamine in the hair, NNK, correlate with the real risk of exposure to the carcinogens in tobacco smoke in passive smokers. This substance is a much better biomarker than any of the markers measured up to now for assessing this risk and it has been found in higher concentrations in the hair than any other tobacco-specific carcinogen. The study was conducted in collaboration with researchers at the Catalan Institute of Oncology (ICO) and has been published in the journal Scientific Reports. The smoke passive smokers are exposed to differs from the smoke of smokers. Passive smokers are exposed to a lot of chemicals resulting from the combustion of the cigarette, but in addition, certain substances have gone through various activation reactions, making them carcinogenic.

    Més informació "Biomarker discovered that measures the risk of cancer in non-smokers"

  • 25/05/2016 - Events

    New evidence on molecular mechanisms involved in psoriasis outset

    Two translational research studies by the University of Barcelona have described new immunologic mechanisms in psoriasis, a chronic cutaneous inflammatory disease which affects around the 2% of the population. The studies, published in the high impact scientific magazines Journal of Allergy and Clinical Immunology and Journal of Investigative Dermatology , have analysed the molecular processes involved in the IL-17 cytokine –a protein family of the immune system- with samples of patients with psoriasis. These results are important to understand the origins of psoriasis and develop more specific pharmaceutical treatments, since the IL-17 blocking is a new therapeutic strategy which is very effective when controlling this illness. The studies have been led by Lluís Francesc Santamaria, Director of the group of Translationary Immunology of the University of Barcelona based at the Barcelona Science Park, together with researchers of the Hospital del Mar and the Municipal Institute for Medical Research, among others.

    Més informació "New evidence on molecular mechanisms involved in psoriasis outset"

  • 09/05/2014 - Events

    GPCR Spring Conference 2014

    Understanding the complex nature of G protein-coupled receptors (GPCR) functionality and exploiting this knowledge for the design of new GPCR modulators has been the central focus of GPCR Spring Conference 2014 organized by the GRIB (IMIM-UPF) researchers Jana Selent and Maria Martí at Barcelona Biomedical Research Park (Barcelona) from 28-30th April. GPCRs are the largest family of proteins involved in signal transduction across membranes and one of the most important pharmaceutical drug target classes. 

    Més informació "GPCR Spring Conference 2014"

  • 20/12/2011 - Events

    Bidding farewell to the participants of the PREDIMED study

    Last 14th December an event was held at the PRBB Auditorium; it was organized by the IMIM Group on Cardiovascular Risk and Nutrition to say goodbye to and thank the participants in the PREDIMED study, their involvement, availability and enthusiasm during the four years over which the project has developed (2003-2011).

    Més informació "Bidding farewell to the participants of the PREDIMED study"

  • 09/03/2011 - Events

    First international index developed to predict suicidal behavior

    Although thousands of people commit suicide worldwide each year, researchers and doctors do not have any method for evaluating a person's likelihood of thinking about or trying to commit suicide. An international group of scientists, in which the IMIM (Hospital del Mar Research Institute) has participated, has devised the first risk index in order to prevent suicides.

    Més informació "First international index developed to predict suicidal behavior"

  • 16/04/2010 - Events

    The chronic lymphocytic leukaemia project reveals the first oncogenic mutations

    The International Cancer Genome Consortium, which will study the genomes of more than 25,000 cancer patients, has presented its latest research results in the journal Nature. The chronic lymphocytic leukemia genome project is coordinated in Spain, and the researcher Nuria López-Bigas, head of Biomedical Genomics laboratory of GRIB (IMIM-UPF) participates on the bioinformatics analysis of data and the coordination and management of Consortium data.

    Més informació "The chronic lymphocytic leukaemia project reveals the first oncogenic mutations"

  • 30/09/2009 - Events

    Open day at PRBB

    On Saturday, October 3, from 10am to 7pm, we invite the citizens to an educational and joyful Open Day at the Barcelona Biomedical Research Park (PRBB). Visitors can participate in scientific experiments, visit laboratories and installations, watch videos, get to know the lines of research of the park, participate in a round-table discussion and talk to the young scientists who will attend all the questions of the public.

    Més informació "Open day at PRBB"


Head of Communications:
Rosa Manaut(ELIMINAR)

Communications office:
Marta Calsina(ELIMINAR)

(+34) 93 316 06 80
(+34) 699 094 833

Doctor Aiguader, 88
08003 Barcelona

© Institut Hospital del Mar
d'Investigacions Mèdiques
Legal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact